MCL1 and plasma cell myeloma: The present study aimed to determine whether the combination of BCL2 inhibitor venetoclax and MCL1 inhibitor S63845 at low doses could be of benefit for myeloma cells beyond the single selective inhibition of BCL2 or MCL1, especially for myeloma cells not dependent on BCL2 or MCL1.